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Abstract
Background: In resource-poor settings, mortality is at its highest during the first 3 months after combination
antiretroviral treatment (cART) initiation. A clear predictor of mortality during this period is having a low CD4 count
at the time of treatment initiation. The objective of this study was to evaluate the effect on survival and clinic
retention of a nurse-based rapid assessment clinic for high-risk individuals initiating cART in a resource-constrained
setting.
Methods: The USAID-AMPATH Partnership has enrolled more than 140,000 patients at 25 clinics throughout
western Kenya. High Risk Express Care (HREC) provides weekly or bi-weekly rapid contacts with nurses for
individuals initiating cART with CD4 counts of ≤100 cells/mm
3. All HIV-infected individuals aged 14 years or older
initiating cART with CD4 counts of ≤100 cells/mm
3 were eligible for enrolment into HREC and for analysis.
Adjusted hazard ratios (AHRs) control for potential confounding using propensity score methods.
Results: Between March 2007 and March 2009, 4,958 patients initiated cART with CD4 counts of ≤100 cells/mm
3.
After adjusting for age, sex, CD4 count, use of cotrimoxazole, treatment for tuberculosis, travel time to clinic and
type of clinic, individuals in HREC had reduced mortality (AHR: 0.59; 95% confidence interval: 0.45-0.77), and
reduced loss to follow up (AHR: 0.62; 95% CI: 0.55-0.70) compared with individuals in routine care. Overall, patients
in HREC were much more likely to be alive and in care after a median of nearly 11 months of follow up (AHR: 0.62;
95% CI: 0.57-0.67).
Conclusions: Frequent monitoring by dedicated nurses in the early months of cART can significantly reduce
mortality and loss to follow up among high-risk patients initiating treatment in resource-constrained settings.
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Background
Combination antiretroviral treatment (cART) has proven
itself to be an effective therapeutic mechanism for sup-
pressing viral replication and enabling reconstitution of
the immune system, thus allowing patients to recover
and live with HIV disease as a chronic illness [1-3]. If
adherence to the medications is high, severe immune-
suppression is not present at cART initiation, and no
significant co-morbidities, such as hepatitis C infection,
exist, projections suggest that people living with HIV/
AIDS have greatly improved long-term prognosis [4].
Despite the proven effectiveness of cART in low-income
countries [5-9], mortality rates among patients in these
settings are higher than those seen in high-income
environments [10].
In resource-poor settings, mortality is at its highest
during the first 3 months after cART initiation [9-12]. It
is at least four times higher than rates in high-income
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mortality is at its highest during this period has been
the subject of much debate and speculation. Reasons for
these differences have been attributed to the non-use of
cotrimoxazole prophylaxis [13,14], tuberculosis-asso-
ciated immune reconstitution inflammatory syndrome
(IRIS) [15-17], IRIS due to other opportunistic infections
[18], and hepatotoxicity related to antiretroviral agents
[19]. A consistently clear predictor of mortality during
this period is having a low CD4 count at the time of
treatment initiation [10,20].
Recent estimates by the World Health Organization
(WHO) indicate that although 6.7 million individuals in
low- and middle-income settings are receiving cART,
this represents only 47% coverage of individuals who are
in clinical need [21]. The massive scale up of HIV care
and treatment programmes has required enormous
investments, and still there is a substantial unmet need.
Thus, the challenge presented to HIV care programmes
operating in resource-poor settings is how to continue
scaling up while simultaneously improving the outcomes
of those enrolling in treatment programmes. As such,
novel models of care, such as task shifting [22-24],
which increase healthcare efficiency and improve patient
outcomes, clearly need to be designed and tested.
H e r e ,w ed e s c r i b et h ei m p a c to fan u r s e - c l i n i c i a n
approach [25] on mortality and patient retention among
severely immune-suppressed HIV-infected adults initiat-
ing cART within a large multi-centre HIV/AIDS care
and treatment programme in western Kenya.
Methods
Study design
This was a retrospective analysis of prospectively col-
lected routine clinical data. The study was approved by
the Indiana University School of Medicine Institutional
Review Board and the Moi University School of Medi-
cine Institutional Review and Ethics Committee.
The programme
The Academic Model Providing Access to Healthcare
(AMPATH) was initiated in 2001 as a joint partnership
between Moi University School of Medicine in Kenya,
the Indiana University School of Medicine, and the Moi
Teaching and Referral Hospital. The USAID-AMPATH
Partnership was initiated in 2004 when AMPATH
received ongoing funding through the United States
Agency for International Development (USAID) and the
United States Presidential Emergency Plan for AIDS
Relief (PEPFAR). The initial goal of AMPATH was to
establish an HIV care system to serve the needs of both
urban and rural patients and to assess the barriers to
and outcomes of antiretroviral therapy. Details of the
development of this programme have been described in
detail elsewhere [26].
The first urban and rural HIV clinics were opened in
November 2001. Since then, the programme has
enrolled more than 140,000 HIV-infected adults and
children in 25 Ministry of Health (MOH) facilities and
numerous satellite clinics in western Kenya (data for
satellite clinics are incorporated into their “parent”
clinic). Although located within the MOH facilities, the
AMPATH clinics are dedicated to HIV and HIV/TB
care, treatment and support. All HIV- and tuberculosis-
related care and treatment are provided free at the point
of care.
Clinical procedures: express care and routine care
The HIV clinical care protocols used by the USAID-
AMPATH Partnership are consistent with those recom-
mended by WHO and have been described in detail
e l s e w h e r e[ 2 7 ] .B r i e f l y ,t h eR o u t i n eC a r ep r o t o c o lf o r
patients receiving cART is that patients are seen by the
clinician (clinical officer or physician) 2 weeks after initi-
ating treatment, and then monthly thereafter. Those
who have not initiated cART return every 1 to 3 months
depending on their clinical status and co-morbidities.
During these visits patients are seen by multiple care
providers, including nurses, clinicians, pharmacy techni-
cians, nutritionists, peer outreach workers and social
workers. For new patients, clinical contact begins at
registration, followed by the nurse who checks vital
signs. The patient also sees a peer outreach worker for
documentation of locator information, then goes on to
see the doctor/clinical officer. Returning patients go
directly to the nurse and then follow a course similar to
that established for new patients. All patients newly
initiated on cART who miss a scheduled clinic visit trig-
ger an outreach attempt within 24 h, through either a
telephone contact or home visit conducted by trained
peers. Standard first-line antiretroviral regimens used
are either nevirapine-based or efavirenz-based [28].
Beginning in March 2007, the High Risk Express Care
(HREC) programme was implemented in a step-wise
fashion in USAID-AMPATH Partnership clinics. As of
May 2008, HREC had been rolled out to all parent
clinics. The selection of clinics to pilot the programme
was based primarily on space availability, patient volume
and clinic congestion, and the general capacity of
healthcare personnel to pilot a new programme. Once a
clinic had implemented HREC, all patients meeting the
criteria for HREC were eligible for referral to the pro-
gramme. The criteria for referral to HREC are having a
C D 4c o u n to f1 0 0c e l l s / m m
3 or less and initiating
cART.
Once a patient is identified as eligible for HREC, the
clinical officer or physician prescribes a two-week supply
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the same clinic location). The patient is seen by a clini-
cal officer or physician 2 weeks after antiretroviral initia-
tion and then monthly. The HREC nurse is then
responsible for interim weekly visits either physically or
by telephone for a period of 3 months. The patient is
seen monthly by a clinical officer or physician. In
HREC, returning patients do not queue in the waiting
bay or go through the nursing station, clinician room,
pharmacy or any other referral points within the clinic.
Instead, such patients go directly to the “Express Care
room”, which provides “one-stop care”.T h eH R E C
nurse maintains a list of scheduled return visits, and if a
patient misses a clinic appointment, the outreach team
is activated as per routine protocol.
The HREC visit for the high-risk patients is focused
on identifying co-morbidities and complications of
cART and reinforcing medication adherence. The nurse
asks about adherence to medication by asking whether
the patient has missed any of his/her medications in the
previous 7 days and then conducting a pill count. If the
patient is not perfectly adherent, he or she is referred to
the clinical officer or physician. The nurse reviews a
symptom checklist (new cough, breathlessness, rash,
jaundiced eyes, vomiting, diarrhoea, severe headache,
fever or “any other problem that you feel you need a
doctor for”) and measures temperature and transcuta-
neous oxygen saturation. If the patient reports any
symptoms or meets the pre-set threshold for either tem-
perature (≥37.2°Celsius) or oxygen saturation (O2 ≤
93%), the patient is referred immediately to the clinical
officer or physician. The nurse does not dispense drugs
during an HREC visit as these are prescribed during
monthly clinical officer or physician visits. A summary
of similarities and differences between HREC and Rou-
tine Care can be found in Table 1.
Data collection
Clinicians complete standardized forms capturing demo-
graphic, clinical and pharmacologic information at each
patient visit. These data are then hand-entered into the
AMPATH Medical Record System, a secure computer-
ized database designed for clinical management, with
data entry validated by random review of 10% of the
forms entered [29]. At the time of registration, patients
are provided with a unique identifying number. For this
study, all data were stripped of identifying information
prior to analysis.
Study population
The analysis included all patients aged 14 years or older
who were initiating cART with CD4 counts less than or
equal to 100 cells/mm
3 in one of the USAID-AMPATH
clinics from March 2007 until March 2009.
Outcomes, explanatory variables and confounders
The primary goal of the HREC system is to prevent
mortality during the first 3 months following cART
initiation. Therefore, the primary outcome for this ana-
lysis was all-cause mortality. Two secondary outcomes
were analyzed: loss to follow up (LTFU), defined as
being absent from the clinic for at least 3 months with
no information regarding vital status, and a composite
outcome defined as LTFU or death. The rationale for
the composite outcome is that loss to follow up in such
a high-risk population is likely to mean that a patient
has died, even if the death has not yet been reported to
the clinic [10,30-34]. Analysis of the composite outcome
can be viewed as a sensitivity analysis for the mortality
rate as it provides an upper bound of the mortality
estimate.
The primary explanatory variable is being in the
HREC programme (versus remaining in Routine Care).
Our analyses quantify the effect of HREC on mortality,
loss to follow up, and the composite outcome of death
or loss to follow up using crude and adjusted hazard
rate (HR) ratios.
Our adjusted HR ratios control for the following
potential confounding variables, all measured at time of
cART initiation and selected ap r i o r ibased on their
potential to independently affect changes in risk of mor-
tality and/or loss to follow up: CD4 count (analyzed as a
continuous variable); receipt of treatment for tuberculo-
sis at the time of cART initiation (yes/no); receipt of
cotrimoxazole or dapsone prophylaxis within 28 days of
cART initiation (yes/no) [13,17]; travel time to clinic
(dichotomized as up to one hour vs. more than one
hour); type of clinic (referral hospital, district or sub-dis-
trict hospital, or rural health centre); age; and sex (male/
female). CD4 and age are centred at their mean values.
Table 1 Summary of programme characteristics in High Risk Express Care (HREC) versus Routine Care
Routine care HREC
Initial clinical assessment Yes No
Prescription of antiretrovirals Yes No
Interim clinical assessments including weight and vital signs Yes, monthly by clinical officer Yes, weekly by nurse and monthly by clinical officer
Adherence monitoring Yes, monthly Yes, weekly
Defaulter tracing Yes, within 24 h Yes, within 24 h
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because: a) it was non-significantly associated with the
outcomes of interest in bivariable analyses; and b) there
was missing data in one of the two groups.
Analysis
We included all eligible patients and categorized them
as having been enrolled into HREC at initiation of
cART or having remained in Routine Care. The distri-
butions of the time to event outcomes are summarized
using Kaplan-Meier curves. Event times and censoring
times are defined as follows: for analysis of mortality,
the event time is the date of death; others are censored
at the time of their last clinic visit. For the analysis of
loss to follow up, patients were defined as lost if they
had not returned to clinic for more than three consecu-
tive months; for these patients, the event time is the
90
th day following the most recent visit to the clinic.
Individuals whose reported follow-up time is zero days
had 1 day added for the purpose of analysis. Those who
died were censored on their death date, and patients
whose most recent clinic was less than 90 days prior to
the close of the database were censored at the date of
their last clinic visit. For the loss to follow up analysis,
the earliest possible event time is 90 days after the
initiation of cART; hence our tests and regression mod-
els use a start time of day 90. Finally, for the composite
outcome, the event time is the earliest of death date or
loss to follow up date, where the LTFU date is defined
as we have explained.
The adjusted HR ratios control for potential con-
founding variables using inverse weighting by the treat-
ment propensity score method [35]. For each individual,
the propensity score is the probability of receiving
HREC as a function of individual level characteristics.
The propensity score, denoted by p(x), is estimated by
fitting a logistic regression model of HREC status (yes/
no) on potential confounding variables x.T h ep r o p e n -
sity score model is checked for lack of fit using the Hos-
mer-Lemeshow goodness-of-fit test [36]. The adjusted
HR ratios are calculated by fitting a weighted, stratified
proportional hazards regression of the event time on
HREC status. The weights are proportional to 1/p(x) for
those who receive HREC, and to 1/{1 - p(x)} for those
who do not. Following Hernan et al. [27], stabilized
weights were used in the estimation (full details are
available upon request). The stratification variable is
clinic type. Robust standard errors are used to account
for clustering by clinic and for correlation induced by
the use of inverse probability weights.
Because the propensity scores represent the probabil-
ity of receiving HREC as a function of individual-level
covariates (listed here), the weight for each individual is
inversely proportional to the (estimated) probability of
his or her actual HREC status. The weighted sample can
therefore be viewed as one where differential selection
into HREC attributable to x has been eliminated; hence,
to the extent that x contains all relevant confounders,
the adjusted HR is equivalent to the exposure effect
from a marginal structural proportional hazards model
and can be interpreted as the causal effect of HREC on
the event of interest [37,38].
All analyses were done using STATA Version SE/10
(College Station, Texas, USA).
Results
There were 4,958 patients aged 14 years or older with
CD4 counts of ≤100 cells/mm
3 who initiated cART at
one of the USAID-AMPATH clinics during the study
period. Of these, 635 were enrolled into HREC. Reasons
why patients were not enrolled into HREC included that
the HREC programme had not yet been rolled out to a
particular clinic, that the patient lived too far to allow
them to attend clinic weekly or bi-weekly, and lack of
available space in the clinic for expansion of the HREC
programme.
As summarized in Table 2 patients in Routine Care
and HREC were similar with regard to gender distribu-
tion and age: 40% male with a median age of approxi-
mately 36 years. There were no significant differences
between the groups with regard to baseline CD4 count
or proportion receiving treatment for tuberculosis.
Patients in HREC were slightly less likely to be WHO
Stage III/IV at cART initiation (66% vs. 69%) and to
have to travel at least 1 h to clinic (71% vs. 77%). They
were more likely to be attending an urban clinic (61%
vs. 52%), and using cotrimoxazole or dapsone prophy-
laxis at cART initiation (100% vs. 95%). The median fol-
low-up time was 318 days (interquartile range 147-533).
There were 426 deaths among the study population:
39 in HREC and 387 in Routine Care. The crude inci-
dence rate of death during the follow-up period was 5.7
per 100 person-years in HREC compared with 10.6 per
100 person-years in Routine Care (incidence rate ratio,
IRR: 0.54; 95% confidence interval, CI: 0.38-0.75) (Figure
1a). After adjustment for potential confounders, the
HREC programme was associated with a 40% reduced
risk of death (adjusted HR: 0.59; 95% CI: 0.45-0.77).
There were also 1,299 patients lost to follow up dur-
ing the same period, including 134 in HREC and 1,165
in Routine Care. The crude incidence rate of LTFU
among HREC was 18.7 per 100 person-years versus 29.7
in Routine Care (IRR: 0.63; 95% CI: 0.52-0.76) (Figure
1b). After adjustment, patients in HREC were also much
less likely to become lost to follow up (AHR 0.62; 95%
CI: 0.55-0.70).
When we assessed the combined endpoint of LTFU
and death, there were 1,725 events in 4639.5 person-
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100 person-years in HREC versus 39.5 in Routine Care
(IRR: 0.61; 95% CI: 0.52-0.72) (Figure 1c). Overall, the
HREC patients were much more likely to be alive and in
care after starting cART by the end of the study follow-
up period (AHR 0.62; 95% CI: 0.57-0.67) (Table 3).
Discussion
The first few months following initiation of cART is a
critical time for severely immune-suppressed HIV-
infected patients. These data suggest that more frequent
monitoring of patients in the early months by a dedi-
cated nurse can significantly improve survival and reten-
tion in care among these high-risk patients and improve
their retention in care. Although further evaluation is
needed, this intervention may be relatively easy to
implement in other resource-constrained environments.
To our knowledge, the concept of frequent nurse-
based rapid assessments is among the few interventions
other than cotrimoxazole prophylaxis that has been
associated with a profound reduction in early mortality
among high-risk HIV-infected patients initiating cART
in low-income settings [13,14]. We believe the effects of
HREC are a combination of the rapid and frequent
assessments. Rapid because this makes accessing health-
care more accessible to patients (by not having to wait
as long and by not having to spend as much time in the
clinic); frequent because it makes it more likely that
early warning symptoms (e.g., fever, rash) can be identi-
fied within days, as opposed to weeks, of their onset. If,
for example, the monthly standard of care visits were
simply made more rapid, such symptoms as fever or
rash would go unattended for potentially weeks, thereby
increasing the risk of full-blown immune-reconstitution
disease, more severe toxicities, etc.
We also postulate that more frequent monitoring is
effective at improving early patient outcomes through
both direct and indirect mechanisms. For example, ear-
lier identification of the signs and symptoms of drug
toxicity, opportunistic infections and immune reconsti-
tution syndrome likely leads to earlier interventions to
address these issues; thus patients should experience a
direct survival advantage in the short-term.
Indirectly, HREC may have improved adherence to cART
and thus improved short-term outcomes. Adherence may
be improved in the HREC population because of the weekly
contact, reminders and supports; as a result of improved
adherence, patients will be more likely to experience com-
plete virologic suppression, have improved immune-
response, and be less likely to develop resistance, therefore
indirectly contributing to survival benefits over the short
and long term. HREC may have improved retention by
enabling patients to be seen quickly without having to wait
in long queues and without having to pass through multiple
stations (i.e., spending much of the day at the clinic),
thereby making their healthcare more accessible to them.
There are some additional costs associated with
HREC. For example, there are added direct costs to
patients arising from increased transportation required
to and from the clinic. They may also have to miss
more work because of more frequent clinic visits, trans-
lating into increased opportunity costs. The nurses hired
to work on HREC were hired explicitly for that purpose,
and this certainly adds to the overall programme
expense on personnel. Whether these additional costs
and expenses are justified when weighed against the
costs associated with increased morbidity, mortality and
loss to follow up is the subject for a detailed cost-effec-
tiveness analysis that is beyond the scope of the present
evaluation.
Table 2 Socio-demographic and clinical characteristics of patients in High Risk Express Care (HREC) versus Routine
Care
Variable HREC n = 635 Routine care n = 4323 p value
Male gender 256 (40%) 1749 (41%) 0.945
Median (IQR) age 35.8 (30.5-42.4) 36.7 (30.6-43.1) 0.097
Median (IQR) CD4 at initiation of cART 46 (20-72) 46 (20-74) 0.908
WHO Clinical Stage III/IV at initiation of cART 418 (66%) 2966 (69%) 0.031
Missing 0 (0%) 89 (2.1%)
On TB treatment at cART initiation 204 (32%) 1514 (35%) 0.152
Clinic type
Referral hospital 217 (34%) 903 (21%) < 0.001
District and sub-district
hospitals
221 (35%) 2107 (49%)
Rural health centres 197 (31%) 1313 (30%)
Use of cotrimoxazole or dapsone within 28 days of cART initiation 632 (100%) 4097 (95%) < 0.001
Travel > 1 h to clinic 452 (71%) 3318 (77%) 0.002
N.B. The only variable for which there were missing data was WHO Stage, as described in the table. This variable was not included in the propensity score model
as it was not a significant predictor of the outcomes of interest
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the standard of care in AMPATH is already to provide
cotrimoxazole or dapsone until a patient’s CD4 count is
above 200 cells/mm
3. These data have therefore been
able to assess the effect of more frequent monitoring in
a setting where the vast majority of patients were
already receiving cotrimoxazole or dapsone. Second, the
effect of HREC was strong across three different ver-
sions of the primary outcome, suggesting a robust effect.
By evaluating the impact of HREC on both mortality
and LTFU, we took account of the two crucial factors
determining the success of an HIV treatment pro-
gramme: keeping patients alive and in care. Moreover,
we used statistical methods that appropriately and
robustly adjusted for measured confounders.
There are also limitations to this analysis. First, the
choice of clinics in which HREC was rolled out to first
m a yh a v ec r e a t e dav a r i e t yo fp o t e n t i a lb i a s e si no u r
analysis related to a possible higher quality of care
offered at those clinics. For example, this may have cre-
ated some selection bias (improved patient outcomes at
those clinics irrespective of HREC, e.g., because of lower
patient volumes, or higher functioning staff), and ascer-
tainment bias (better ascertainment of death and other
clinical outcomes at the higher functioning clinics).
Similarly, although all patients were eligible to be
enrolled into HREC, only a small proportion were
enrolled. If the providers who were more likely to refer
patients to HREC were also the ones more likely to be
current with clinical protocols (i.e., to prescribe cotri-
moxazole) and/or more likely to be better clinicians,
those patients referred by them may have been more
likely to have better outcomes anyway.
However, for those patients referred, it was the
HREC nurse who had the majority of clinical contact
with them, thereby reducing any potential provider
bias on the part of the referring clinician. Similarly, a
slightly smaller proportion of patients enrolled into
HREC were WHO Stage III/IV at treatment initiation.
Although these issues may have biased the findings
favourably towards HREC, the use of propensity score
methods helps to overcome this possible bias because
weighting in inverse proportion to the treatment pro-
pensity score creates a pseudo-sample wherein alloca-
tion to HREC is independent of the confounders that
have been included in the propensity score. Hence the
weighted dataset can be analyzed as if the group allo-
cation were random. A limitation of this method is
that there may be non-random allocation to HREC
based on unmeasured factors to the extent that receipt
of HREC depends on unmeasured factors. We
acknowledge that residual bias may therefore remain
due to potential unmeasured confounders, including
adherence to cART (not accounted for in this analysis
due to unreliability of the data).
Conclusions
In conclusion, we have demonstrated that weekly rapid
assessments by nurses, either by phone or in person,
Figure 1 Kaplan-Meier curves demonstrating the effect of the
High Risk Express Care compared with Routine Care among all
high-risk patients on: a) their probability of survival; b) their
probability of remaining in care (i.e., loss to follow up); and c)
their probability of remaining alive and in care (n = 4958). a
Probability of remaining alive after cART initiation. b
Probability of remaining in care after cART initiation. c
Probability of remaining alive and in care after cART.
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cians if needed, can significantly improve survival
among high-risk HIV-infected patients initiating cART
in a sub-Saharan African setting. Although the cost
effectiveness of the Express Care model needs to be
thoroughly evaluated, our experience and findings sug-
g e s tt h a tt h i sm a yb ea ni n n o v a t i v ew a yo fi n c r e a s i n g
patient volume, improving the quality of care, and
greatly improving patient outcomes in the short term.
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